Amendments to the Claims:

Please amend Claims 1, 3, 4, 6, 8 and 12, cancel Claims 2, 7, 9-11 and 13-23 and add new Claims 24-33. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (currently amended): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety selected from the group consisting of thrombin, fibronectin, bacterial fibrinogen binding proteins, basic fibrinogen growth factor, integrins, and moieties derived from any member of this group,

a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance, and

a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

2 (canceled)

3 (currently amended): The conjugate of claim 1, wherein said substance capturing moiety is an antibody, a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

4 (currently amended): The conjugate of claim 1, wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound-healing substances, and imaging agents.

5 (original): The conjugate of claim 1, wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

Appl. No. 10/749,832 Amdt. dated June 20, 2005 Reply to Office Action of February 18, 2005

6 (currently amended): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety selected from the group consisting of thrombin, fibronectin, bacterial fibrinogen binding proteins, basic fibrinogen growth factor, integrins, and moieties derived from any member of this group,

a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance.

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

7 (canceled)

8 (currently amended): The conjugate of claim [[7]] 6 wherein said fibrin/fibrinogen-binding moiety is covalently bound to said pharmaceutically active substance and said substance capturing moiety are covalently bound.

9-11 (canceled)

12 (currently amended): The conjugate of claim [[8]] 6 wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound healing substances, and imaging agents.

13-23 (canceled)

24 (new): The conjugate of claim 6, wherein said substance capturing moiety is an antibody or part thereof which specifically recognizes said pharmaceutically active substance.

25 (new): The conjugate of claim 1, wherein said substance capturing moiety is a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

26 (new): The conjugate of claim 6, wherein said substance capturing moiety is a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

Appl. No. 10/749,832 Amdt. dated June 20, 2005 Reply to Office Action of February 18, 2005

- 27 (new): The conjugate of claim 1, wherein said pharmaceutically active substance is a wound healing substance.
- 28 (new): The conjugate of claim 6, wherein said pharmaceutically active substance is a wound healing substance.
 - 29 (new): Fibrin/fibrinogen-binding conjugate comprising a fibrin/fibrinogen-binding moiety that is a nucleic acid,
- a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

- 30 (new): The conjugate of claim 29, wherein said substance capturing moiety is an antibody, a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.
- 31 (new): The conjugate of claim 29, further comprising a pharmaceutically active substance.
- 32 (new): The conjugate of claim 31, wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound-healing substances, and imaging agents.
- 33 (new): The conjugate of claim 29, wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.